An Edward Lifesciences Sapien TAVR valve during an implant procedure on angiography. There are still questions on how to best anticoagulate TAVR patients and the ATLANTIS study found Eloquis is not a good solution.

An Edward Lifesciences Sapien TAVR valve during an implant procedure on angiography. There are still questions on how to best anticoagulate TAVR patients and the ATLANTIS study found Eliquis is not a good solution.

News | Structural Heart | May 15, 2021
May 15, 2021 — The anticoagulant apixaban (Eliquis) was not superior to standard of care following transcatheter aortic...
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal...
A device programmer showing the suspension of ICD therapies (orange bar, red arrow) with iPhone 12 laying over patient’s chest (green arrow) and fluoroscopy of iPhone 12 showing the circular magnet array (yellow arrow). Image from a small study at Henry Ford Hospital. Read the full study

A device programmer showing the suspension of ICD therapies (orange bar, red arrow) with iPhone 12 laying over patient’s chest (green arrow) and fluoroscopy of iPhone 12 showing the circular magnet array (yellow arrow). Image from a small study at Henry Ford Hospital. Read the full study

News | EP Lab | May 14, 2021
May 14, 2021 — The U.S. Food and Drug Administration (FDA) is advising patients and caregivers to keep any consumer...
Abbott Recalls Assurity and Endurity Pacemakers 
News | EP Lab | May 14, 2021
May 14, 2021 — Abbott is recalling a subset of Assurity and Endurity pacemakers built using specific manufacturing...
According to the CDC, if you are fully vaccinated you can start doing many things that you had stopped doing because of the pandemic. Infographic courtesy of the CDC.

According to the CDC, if you are fully vaccinated you can start doing many things that you had stopped doing because of the pandemic. Infographic courtesy of the CDC.

News | Coronavirus (COVID-19) | May 13, 2021
May 13, 2021 — The Centers for Disease Control and Prevention (CDC) just released a new statement relaxing the...
Explaining the Emory TMVR angle. Discordance between mitral annular centerline (yellow lines) and valve orientation imposed by guidewire position within the LV apex (red dashed lines). (B) Valve intrinsic angle (α) is determined by external skirt height. (C) When annular-apical “Emory” angle (red curves) exceeds α (blue curve), annular skirt apposition is not possible, causing PVL (red arrows). (D) The valve is oriented perpendicular to the annual plane using an exteriorized apical guidewire.

Explaining the Emory TMVR angle. Discordance between mitral annular centerline (yellow lines) and valve orientation imposed by guidewire position within the LV apex (red dashed lines). (B) Valve intrinsic angle (α) is determined by external skirt height. (C) When annular-apical “Emory” angle (red curves) exceeds α (blue curve), annular skirt apposition is not possible, causing PVL (red arrows). (D) The valve is oriented perpendicular to the annual plane using an exteriorized apical guidewire (solid yellow line). Image courtesy of Kendra Grubb, M.D.

Feature | Structural Heart | May 13, 2021 | By Dave Fornell, Editor
The mitral valve anatomy is extremely complex, which has caused many challenges for transcatheter mitral valve...
Videos | Structural Heart | May 13, 2021
Tom Jones, M.D., director, cardiac catheterization laboratories, Seattle Children’s Hospital, and principle...
Estimates of excess deaths, defined as the number of persons who have died from all causes, above the expected number of deaths for a given place and time, can provide a comprehensive account of mortality likely related to the COVID-19 pandemic, including deaths that are both directly and indirectly associated with COVID-19

Getty Images

News | Coronavirus (COVID-19) | May 13, 2021
May 13, 2021 — Estimates of excess deaths, defined as the number of persons who have died from all causes, above the...
PolyVascular, leading the effort to improve children's lives with a novel polymeric transcatheter valve (PTV) for children, announced that it was awarded a $2 million Small Business Innovation Research (SBIR) Phase II grant earlier this year to bring its polymeric stent-mounted valve (SMV) to clinical trials within the next two years in an effort to address pediatric congenital heart disease (CHD), which affects over 1 million patients around the world.
News | Pediatric Cardiology | May 13, 2021
May 13, 2021 — PolyVascular, leading the effort to improve children's lives with a novel polymeric transcatheter valve...
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has...
According to the British Heart Foundation, heart and circulatory diseases cause more than a quarter (27 percent) of all deaths in the UK, which equates to more than 160,000 deaths each year — or one death every three minutes.
News | Cardiac Imaging | May 12, 2021
May 12, 2021 — According to the British Heart Foundation, heart and circulatory diseases cause more than a quarter (27...
Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a new, low-profile thoracic aortic endograft is safe and effective in the treatment of descending thoracic aortic aneurysm or penetrating atherosclerotic ulcer (PAU) diseases.
News | Endovascular Aortic Repair | May 12, 2021
May 12, 2021 — Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a...
EP lab at the University of Colorado
News | EP Lab | May 12, 2021
May 12, 2021 — Galaxy Medical and Japan Lifeline announced an exclusive distribution agreement for the Alpha1 ablation...
The digital technology is reducing reliance on unnecessary invasive diagnostic procedures and is cutting hospital waiting times
News | Artificial Intelligence | May 12, 2021
May 12, 2021 — HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced that the National...
The BioCardia cardiac stem cell CardiAMP trial is a Phase III study looking at the efficacy of using stem cells to improve heart function in heart failure patients. It is the first trial for this technology to reach Phase III trial.

The BioCardia cardiac stem cell CardiAMP trial is a Phase III study looking at the efficacy of using stem cells to improve heart function in heart failure patients. It is the first trial for this technology to reach Phase III trial.

Feature | Stem Cell Therapies | May 11, 2021 | By Simon H. Stertzer, M.D.
Heart failure remains an unheralded global pandemic, costing society billions of dollars each year.[1,2] Projections...